TAB3

Across TCGA pan-cancer cohorts, TAB3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TAB3 data layer compared with 24 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher TAB3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated TAB3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, CCRCC, and HNSC are the cancer types where TAB3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	1.000	0.747	.002	11	view →
CCRCC	DFS	Median	III,IV	1.000	0.451	.032	8	view →
HNSC	OS	Median	II,III,IV	0.788	0.928	.017	7	view →
GBM	DFS	Median	All	0.312	0.434	.030	2	view →
LSCC	DFS	Tertile	II,III,IV	0.529	1.000	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

TAB3–LUAD (OS)

Open the LUAD breakdown →